Trials / Completed
CompletedNCT01798303
A Study of LY2940094 in Participants With Alcohol Dependency
Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Patients With Alcohol Dependence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- BlackThorn Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants. The study will last for 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940094 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2013-02-25
- Last updated
- 2017-02-03
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01798303. Inclusion in this directory is not an endorsement.